Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00738400
Recruitment Status : Completed
First Posted : August 20, 2008
Results First Posted : June 1, 2011
Last Update Posted : November 16, 2015
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a controlled, randomized, multi-center prospective study of vardenafil to determine efficacy on Erectile Dysfunction (ED), tolerability and safety in men with ED and Metabolic Syndrome. This study will explore the rate of patients who do need to switch to the highest dosage based upon the expectation that most men can stay on vardenafil 10 mg PRN (pro re nata)

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Metabolic Syndrome Drug: Vardenafil (Levitra, BAY38-9456) Drug: Placebo Phase 4

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind, Placebo Controlled, Randomized Study of Vardenafil to Determine Efficacy on Erectile Dysfunction (ED) in Men With ED and Metabolic Syndrome (ED-METABOLIC)
Study Start Date : November 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Vardenafil (Levitra, BAY38-9456)
Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
 Drug: Vardenafil (Levitra, BAY38-9456)
Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
Placebo Comparator: Placebo
Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
 Drug: Placebo
Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change From Baseline in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Subscore at Week 8 or Last Observation Carried Forward (LOCF) [ Time Frame: baseline and up to 8 weeks or LOCF ]
    The primary variable was the least square (LS)-mean difference between treatment groups in the IIEF-EF domain score (6-30 ordinal points, specifying the severity of erectile dysfunction: 6-10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; 26-30 'no erectile dysfunction [ED]'). The target variable is the LS-mean difference between treatment groups at endpoint. The LS-means of both treatment groups are derived from a baseline-adjusted endpoint measure (week 8/last observation carried forward [LOCF]) as calculated via an ANCOVA.

  2. Change in Percentage From Baseline in Success of Penetration (SEP2: Sexual Encounter Profile Question 2) at Week 8 [ Time Frame: Baseline and 8 weeks ]
    Percent successful penetrations were calculated per participant as the number of successful sexual attempts (penetrations) divided by the total number of attempts. The mean percent successful penetrations was then calculated across all participants.

  3. Change in Percentage From Baseline in Success of Erection Maintenance (SEP3: Sexual Encounter Profile Question 3) at Week 8 [ Time Frame: Baseline and 8 weeks ]
    Percent successful maintenance of erection were calculated per participant as the number of successful attempts (maintenance of erection) divided by the total number of attempts. The mean percent successful maintenance of erection was then calculated across all participants.


Secondary Outcome Measures :
  1. Percentage of Participants Achieving "Back to Normal" Erectile Function at Week 8 or Last Observation Carried Forward (LOCF) [ Time Frame: up to 8 weeks or LOCF ]
    Responders: percentage of participants achieving an IIEF-EF score >25.(IIEF-EF domain score: 6-30 ordinal points, specifying the severity of erectile dysfunction: 6-10 'severe'; 11-16 'moderate'; 17-21 'mild to moderate'; 22-25 'mild'; 26-30 'no ED')

  2. Change in Percentage From Baseline in Ability to Obtain an Erection (SEP1) at Week 8 [ Time Frame: Baseline and 8 weeks ]
    Percent successful erections were calculated per participant as the number of successful attempts (achievement of erection) divided by the total number of attempts. The mean percent successful erections was then calculated across all participants.

  3. Change in Percentage From Baseline in Ability to Ejaculate (SEP6) at Week 8 [ Time Frame: Baseline and 8 weeks ]
    Percent successful ejaculations were calculated per participant as the number of successful attempts (achievement of ejaculation) divided by the total number of attempts. The mean percent successful ejaculations was then calculated across all participants.

  4. Number of Participants Who Can Stay on the Initially Provided Dosage of Vardenafil (10 mg PRN (Pro re Nata)) [ Time Frame: week 4 and week 8 ]
    Number of participants with no recorded titration of Vardenafil after visit 3.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable heterosexual relationship
  • History of erectile dysfunction for at least 6 months
  • IIEF- EF Domain entry score (at Visit 2): >21 points
  • Documented metabolic syndrome according to the IDF (International Diabetes Foundation)
  • Subjects motivated for erectile dysfunction treatment
  • Documented, dated, written informed consent

Exclusion Criteria:

  • Any underlying cardiovascular condition
  • History of myocardial infarction
  • Uncontrolled atrial fibrillation
  • Resting hypotension
  • Postural hypotension within 6 months of Visit 1
  • History of congenital QT prolongation
  • Bleeding disorder
  • History of prostatectomy because of prostate cancer
  • Hereditary degenerative retinal disorders
  • History of loss of vision because of NAION (non-arteritic anterior ischemic optic neuropathy)
  • 29 Additional Exclusion Criteria
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00738400


Locations
Layout table for location information
Germany
Cham, Bayern, Germany, 93413
Regensburg, Bayern, Germany, 93055
Frankfurt, Hessen, Germany, 60385
Marburg, Hessen, Germany, 35039
Stuhr, Niedersachsen, Germany, 28816
Bonn, Nordrhein-Westfalen, Germany, 53119
Grevenbroich, Nordrhein-Westfalen, Germany, 41515
Leverkusen, Nordrhein-Westfalen, Germany, 51373
Mülheim, Nordrhein-Westfalen, Germany, 45468
Wuppertal, Nordrhein-Westfalen, Germany, 42103
Dierdorf, Rheinland-Pfalz, Germany, 56269
Koblenz, Rheinland-Pfalz, Germany, 56068
Trier, Rheinland-Pfalz, Germany, 54290
Homburg, Saarland, Germany, 66424
Dresden, Sachsen, Germany, 01307
Leipzig, Sachsen, Germany, 04109
Berlin, Germany, 12107
Berlin, Germany, 14197
Hamburg, Germany, 20354
Sponsors and Collaborators
Bayer
Investigators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00738400    
Other Study ID Numbers: 13171
2008-002140-41 ( EudraCT Number )
ED-METABOLIC ( Other Identifier: Company Internal )
First Posted: August 20, 2008    Key Record Dates
Results First Posted: June 1, 2011
Last Update Posted: November 16, 2015
Last Verified: November 2015
Keywords provided by Bayer:
Vardenafil
Erectile Dysfunction
Double-blind study
Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Metabolic Syndrome
Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Sexual Dysfunction, Physiological
 Sexual Dysfunctions, Psychological
Mental Disorders
Vardenafil Dihydrochloride
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents